TY - JOUR AU - Dardano, A. AU - Penno, G. AU - Prato, S. D. AU - Miccoli, R. PY - 2014 DA - 2014// TI - Optimal therapy of type 2 diabetes: a controversial challenge JO - Aging VL - 6 UR - https://doi.org/10.18632/aging.100646 DO - 10.18632/aging.100646 ID - Dardano2014 ER - TY - BOOK AU - Rang, H. P. PY - 2003 DA - 2003// TI - Pharmacology PB - Churchill Livingstone CY - New York ID - Rang2003 ER - TY - JOUR AU - Zhou, G. AU - Myers, R. AU - Li, Y. PY - 2001 DA - 2001// TI - Role of AMP activated protein kinase in mechanism of metformin action JO - J Clin Invest VL - 108 UR - https://doi.org/10.1172/JCI13505 DO - 10.1172/JCI13505 ID - Zhou2001 ER - TY - JOUR AU - Mu, J. AU - Brozinick, J. T. AU - Valladares, O. PY - 2001 DA - 2001// TI - A role for AMP-activated protein kinase in con- traction- and hypoxia-regulated glucose transport in skeletal muscle JO - Mol Cell VL - 7 UR - https://doi.org/10.1016/S1097-2765(01)00251-9 DO - 10.1016/S1097-2765(01)00251-9 ID - Mu2001 ER - TY - JOUR AU - Fryer, L. G. AU - Parbu-Patel, A. AU - Carling, D. PY - 2002 DA - 2002// TI - The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways JO - J Biol Chem VL - 277 UR - https://doi.org/10.1074/jbc.M202489200 DO - 10.1074/jbc.M202489200 ID - Fryer2002 ER - TY - JOUR AU - Sahra, I. B. AU - Marchand-Brustel, Y. L. AU - Tanti, J. AU - Bost, F. PY - 2010 DA - 2010// TI - Metformin in Cancer therapy: a new perspective for an old Antidiabetic drug? JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-09-1186 DO - 10.1158/1535-7163.MCT-09-1186 ID - Sahra2010 ER - TY - JOUR AU - Zakikhani, M. AU - Dowling, R. AU - Fantus, I. G. PY - 2006 DA - 2006// TI - Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-1500 DO - 10.1158/0008-5472.CAN-06-1500 ID - Zakikhani2006 ER - TY - JOUR AU - Franciosi, M. AU - Lucisano, G. AU - Lapice, E. PY - 2013 DA - 2013// TI - Metformin therapy and risk of Cancer in patients with type 2 diabetes: systematic review JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0071583 DO - 10.1371/journal.pone.0071583 ID - Franciosi2013 ER - TY - JOUR AU - Cerezo, M. AU - Tomic, T. AU - Ballotti, R. AU - Rocchi, S. PY - 2014 DA - 2014// TI - Is it time to test biguanide metformin in the treatment of melanoma? JO - Pigment Cell Melanoma Res VL - 28 UR - https://doi.org/10.1111/pcmr.12267 DO - 10.1111/pcmr.12267 ID - Cerezo2014 ER - TY - JOUR AU - Gwinn, D. M. AU - Shackelford, D. B. AU - Egan, D. F. PY - 2008 DA - 2008// TI - AMPK phosphorylation of raptor mediates a metabolic checkpoint JO - Mol Cell VL - 30 UR - https://doi.org/10.1016/j.molcel.2008.03.003 DO - 10.1016/j.molcel.2008.03.003 ID - Gwinn2008 ER - TY - JOUR AU - Buzzai, M. AU - Jones, R. G. AU - Amaravadi, R. K. PY - 2007 DA - 2007// TI - Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-4447 DO - 10.1158/0008-5472.CAN-06-4447 ID - Buzzai2007 ER - TY - JOUR AU - Algire, C. AU - Amrein, L. AU - Zakikhani, M. AU - Panasci, L. AU - Pollak, M. PY - 2010 DA - 2010// TI - Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase JO - Endocr Relat Cancer VL - 17 UR - https://doi.org/10.1677/ERC-09-0252 DO - 10.1677/ERC-09-0252 ID - Algire2010 ER - TY - JOUR AU - Vallianou, N. G. AU - Evangelopoulos, A. AU - Kazazis, C. PY - 2013 DA - 2013// TI - Metformin and Cancer JO - Rev Diabet Stud VL - 10 UR - https://doi.org/10.1900/RDS.2013.10.228 DO - 10.1900/RDS.2013.10.228 ID - Vallianou2013 ER - TY - JOUR AU - Song, C. W. AU - Lee, H. AU - Dings, R. P. M. PY - 2012 DA - 2012// TI - Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells JO - Sci Rep VL - 2 UR - https://doi.org/10.1038/srep00362 DO - 10.1038/srep00362 ID - Song2012 ER - TY - STD TI - SEER Stat Fact Sheets: Melanoma of the Skin. Available at: https://seer.cancer.gov/statfacts/html/melan.html. Retrieved on 6/13/2018. UR - https://seer.cancer.gov/statfacts/html/melan.html ID - ref15 ER - TY - JOUR AU - Thiery, J. P. AU - Sleeman, J. P. PY - 2006 DA - 2006// TI - Complex networks orchestrate epithelial- mesenchymal transitions JO - Nat Rev Mol Cell Biol VL - 7 UR - https://doi.org/10.1038/nrm1835 DO - 10.1038/nrm1835 ID - Thiery2006 ER - TY - JOUR AU - Nakamura, M. AU - Tokura, Y. PY - 2011 DA - 2011// TI - Epithelial-mesenchymal transition in the skin JO - J Dermatol Sci VL - 61 UR - https://doi.org/10.1016/j.jdermsci.2010.11.015 DO - 10.1016/j.jdermsci.2010.11.015 ID - Nakamura2011 ER - TY - JOUR AU - Cerezo, M. AU - Tichet, M. AU - Abbe, P. PY - 2013 DA - 2013// TI - Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-12-1226-T DO - 10.1158/1535-7163.MCT-12-1226-T ID - Cerezo2013 ER - TY - JOUR AU - Tomic, T. AU - Botton, T. AU - Cerezo, M. PY - 2011 DA - 2011// TI - Metformin inhibits melanoma development through autophagy and apoptosis mechanisms JO - Cell Death Dis VL - 2 UR - https://doi.org/10.1038/cddis.2011.86 DO - 10.1038/cddis.2011.86 ID - Tomic2011 ER - TY - JOUR AU - Smalley, K. S. PY - 2010 DA - 2010// TI - PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma JO - Curr Opin Investig Drugs VL - 11 ID - Smalley2010 ER - TY - JOUR AU - Russell, W. J. AU - Barbie, D. A. AU - Flaherty, K. T. PY - 2018 DA - 2018// TI - Mechanisms of resistance to immune checkpoint inhibitors JO - Br J Cancer VL - 118 UR - https://doi.org/10.1038/bjc.2017.434 DO - 10.1038/bjc.2017.434 ID - Russell2018 ER - TY - JOUR AU - Aplin, A. E. AU - Kaplan, F. M. AU - Shao, Y. PY - 2011 DA - 2011// TI - Mechanisms of resistance to RAF inhibitors in melanoma JO - J Invest Dermatol VL - 131 UR - https://doi.org/10.1038/jid.2011.147 DO - 10.1038/jid.2011.147 ID - Aplin2011 ER - TY - JOUR AU - Livingstone, E. AU - Swann, S. AU - Lilla, C. AU - Schadendorf, D. AU - Roesch, A. PY - 2015 DA - 2015// TI - Combining BRAFV600E inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma JO - Exp Dermatol VL - 24 UR - https://doi.org/10.1111/exd.12718 DO - 10.1111/exd.12718 ID - Livingstone2015 ER - TY - JOUR AU - Montaudié, H. AU - Cerezo, M. AU - Bahadoran, P. PY - 2017 DA - 2017// TI - Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit JO - Pigment Cell & Melanoma Research VL - 30 UR - https://doi.org/10.1111/pcmr.12576 DO - 10.1111/pcmr.12576 ID - Montaudié2017 ER - TY - JOUR AU - Scharping, N. E. AU - Menk, A. V. AU - Whetstone, R. D. PY - 2016 DA - 2016// TI - Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0103 DO - 10.1158/2326-6066.CIR-16-0103 ID - Scharping2016 ER - TY - JOUR AU - Kim, S. H. AU - Man, L. AU - Trousil, S. PY - 2017 DA - 2017// TI - Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma JO - J Investig Dermatol VL - 137 UR - https://doi.org/10.1016/j.jid.2017.03.033 DO - 10.1016/j.jid.2017.03.033 ID - Kim2017 ER - TY - JOUR AU - Marvel, D. AU - Gabrilovich, D. I. PY - 2015 DA - 2015// TI - Myeloid-derived suppressor cells in the tumor micro- environment: expect the unexpected JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80005 DO - 10.1172/JCI80005 ID - Marvel2015 ER - TY - JOUR AU - Eisenhauer, E. AU - Therasse, P. AU - Bogaerts, J. AU - Shankar, L. PY - 2008 DA - 2008// TI - 32 INVITED new response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 JO - Eur J Cancer Suppl VL - 6 UR - https://doi.org/10.1016/S1359-6349(08)71964-5 DO - 10.1016/S1359-6349(08)71964-5 ID - Eisenhauer2008 ER - TY - STD TI - Stat Trek: Teach Yourself Statistics. Available at: http://stattrek.com/statistics/random-number-generator.aspx. Retrieved on 3/17/2018. UR - http://stattrek.com/statistics/random-number-generator.aspx ID - ref29 ER - TY - JOUR AU - Johnson, D. B. AU - Lovly, C. M. AU - Flavin, M. PY - 2015 DA - 2015// TI - Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-14-0207 DO - 10.1158/2326-6066.CIR-14-0207 ID - Johnson2015 ER - TY - JOUR AU - Masback, A. AU - Olsson, H. AU - Westerdahl, J. PY - 2001 DA - 2001// TI - Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review JO - Melanoma Res VL - 11 UR - https://doi.org/10.1097/00008390-200110000-00001 DO - 10.1097/00008390-200110000-00001 ID - Masback2001 ER - TY - JOUR AU - Vossaert, K. A. AU - Silverman, M. K. AU - Kopf, A. W. PY - 1992 DA - 1992// TI - Influence of gender on survival in patients with stage I malignant melanoma JO - J Am Acad Dermatol VL - 26 UR - https://doi.org/10.1016/0190-9622(92)70068-Q DO - 10.1016/0190-9622(92)70068-Q ID - Vossaert1992 ER - TY - JOUR AU - Schuchter, L. AU - Schultz, D. J. AU - Synnestvedt, M. PY - 1996 DA - 1996// TI - A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group JO - Ann Intern Med VL - 125 UR - https://doi.org/10.7326/0003-4819-125-5-199609010-00003 DO - 10.7326/0003-4819-125-5-199609010-00003 ID - Schuchter1996 ER - TY - JOUR AU - Chang, C. K. AU - Jacobs, I. A. AU - Vizgirda, V. M. PY - 2003 DA - 2003// TI - Melanoma in the elderly patient JO - Arch Surg VL - 138 UR - https://doi.org/10.1001/archsurg.138.10.1135 DO - 10.1001/archsurg.138.10.1135 ID - Chang2003 ER - TY - JOUR AU - Balch, C. M. AU - Soong, S. J. AU - Gershenwald, J. E. PY - 2001 DA - 2001// TI - Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on Cancer melanoma staging system JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.16.3622 DO - 10.1200/JCO.2001.19.16.3622 ID - Balch2001 ER - TY - JOUR AU - Failing, J. J. AU - Finnes, H. D. AU - Kottschade, L. A. AU - Allred, J. B. AU - Markovic, S. N. PY - 2016 DA - 2016// TI - Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma JO - Melanoma Res VL - 26 UR - https://doi.org/10.1097/CMR.0000000000000299 DO - 10.1097/CMR.0000000000000299 ID - Failing2016 ER - TY - STD TI - A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients - Full Text View. Full Text View - ClinicalTrials.Gov, clinicaltrials.gov/ct2/show/NCT01638676. UR - http://clinicaltrials.gov/ct2/show/NCT01638676 ID - ref37 ER - TY - STD TI - Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients - Full Text View. Full Text View - ClinicalTrials.Gov, clinicaltrials.gov/ct2/show/NCT02143050. UR - http://clinicaltrials.gov/ct2/show/NCT02143050 ID - ref38 ER -